Recommendations for cancer prevention trials using potentially ototoxic test agents

L I Shotland1, F G Ondrey, K A Mayo

  • 1Hearing Section, Neuro-Otology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892, USA.

Summary

Preventive oncology agents require careful monitoring for hearing loss. New audiologic recommendations help distinguish drug-induced ototoxicity from age-related hearing changes.